 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || ART-I02 / MeiraGTx
Clinical, P1/2 data, Journal: Administration of an adeno-associated viral vector expressing interferon-β in patients with inflammatory hand arthritis, results of a phase I/II study. (Pubmed Central) - Mar 11, 2022
P1
Single IA doses of 0.6x10 or 1.2x10 ART-I02 vector genomes were administered without systemic side effects or serious AEs. However, local tolerability was insufficient for continuation.
- | ART-I02 / MeiraGTx
Enrollment closed: ART-I02 in Patients With Rheumatoid Arthritis With Inflamed Wrists (clinicaltrials.gov) - Nov 14, 2018
P1, N=15, Active, not recruiting, Sponsor: Arthrogen
However, local tolerability was insufficient for continuation. Recruiting --> Active, not recruiting
- | ART-I02 / MeiraGTx
New P1 trial: ART-I02 in Patients With Rheumatoid Arthritis With Inflamed Wrists (clinicaltrials.gov) - Feb 25, 2018
P1, N=15, Recruiting, Sponsor: Arthrogen